A research team from the United States and Canada has developed and successfully tested new computational software that determines whether a human DNA sample includes an epigenetic add-on linked to cancer and other adverse health conditions. In the Feb. 20 issue of the journal Nature Methods, team members from Johns Hopkins University, the Ontario Institute for Cancer Research and the University of Toronto detailed their promising new method of detecting the presence of an extra mark on DNA called cytosine methylation...
Reza Moridi
See the following -
New Gene Sequencing Software Could Aid in Early Detection, Treatment of Cancer
Press Release |
Johns Hopkins University |
February 23, 2017
- Login to post comments
New Open Source Gene Sequencing Software Could Aid in Early Detection, Treatment of Cancer
Press Release |
Johns Hopkins University |
February 23, 2017
A research team from the United States and Canada has developed and successfully tested new computational software that determines whether a human DNA sample includes an epigenetic add-on linked to cancer and other adverse health conditions. In the Feb. 20 issue of the journal Nature Methods, team members from Johns Hopkins University, the Ontario Institute for Cancer Research and the University of Toronto detailed their promising new method of detecting the presence of an extra mark on DNA called cytosine methylation...
- Login to post comments
The Ontario Institute for Cancer Research and the Structural Genomics Consortium develop and give away new drug-like molecule to help crowd-source cancer research.
Press Release |
Ontario Institute for Cancer Research, Structural Genomics Consortium |
September 3, 2015
Through a novel open source approach the molecule has been made freely available to the cancer research community to help discover new therapeutic strategies for cancer patients sooner...Researchers from the Ontario Institute for Cancer Research (OICR) and the Structural Genomics Consortium (SGC) at the MaRS Discovery District in Toronto have developed a new drug prototype called OICR-9429 and made it freely available to the research community. Already research conducted by international groups using OICR-9429 has shown it to be effective in stopping cancer cell growth in breast cancer cell lines and a specific subtype of leukemia cells.
- Login to post comments
Copyright ©2011-2020 Open Health Marketplace, LLC. All Rights Reserved.